Folate-Targeted Photodynamic Agents for Organelle-Specific Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as surgery, radiation therapy, and chemotherapy, are ineffective against metastatic disease and often cause significant side effects due to non-specific targeting, and existing imaging agents for image-guided surgery lack sensitivity and specificity for tumor tissue.
Innovation Solution
Development of folate-targeted photodynamic therapeutic agents conjugated to a ligand that selectively targets the mitochondria or nucleus within diseased cells, using a releasable linker to enhance water solubility and specificity, thereby overcoming the limitations of conventional therapies and imaging agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (surgery, radiation, chemotherapy) are used, then cancer treatment is provided, but they are ineffective against metastatic disease and cause significant side effects due to non-specific targeting
Solution Approach 1:
The patent applies local quality by designing photodynamic therapeutic agents with specific organelle-targeting capabilities (mitochondria or nucleus targeting) combined with folate receptor targeting. This creates a dual-specificity system that concentrates the therapeutic effect at a very localized level within the tumor cell, improving effectiveness against metastatic disease while minimizing harmful effects on healthy tissues through precise spatial confinement of the phototoxic agent.
Solution Approach 2:
The patent uses an intermediary approach by employing a releasable linker between the folate-targeting moiety and the photodynamic agent. This linker acts as a controlled-release mechanism that maintains stability in circulation but releases the active photodynamic agent inside the target cell, enabling specific targeting while controlling the timing and location of therapeutic action to reduce off-target effects.
2Measurement precision
If imaging agents are used for image-guided surgery, then tumor localization is attempted, but they lack sensitivity and specificity for tumor tissue
Solution Approach 1:
The patent applies universality by designing photodynamic agents that simultaneously serve dual functions: they act as both imaging agents (through fluorescent properties) and therapeutic agents (through photodynamic activity). The folate-targeted photodynamic agents with organelle-specific targeting moieties provide enhanced sensitivity and specificity for tumor tissue detection while also delivering therapeutic effect, eliminating the need for separate imaging and therapy agents.
Solution Approach 2:
The patent enhances imaging precision by incorporating organelle-targeting moieties (mitochondria or nucleus targeting) that concentrate the imaging signal within specific subcellular compartments of tumor cells. This local quality enhancement provides superior sensitivity and specificity for detecting tumor tissue compared to conventional imaging agents that lack subcellular targeting capability.
3Reliability
If photodynamic agents are conjugated to ligands for targeted delivery, then specificity is improved, but water solubility and pharmacokinetic properties must be optimized
Solution Approach 1:
The patent uses a releasable linker as an intermediary component that connects the hydrophilic folate ligand to the photodynamic agent. This linker serves multiple functions: it maintains the water solubility and favorable pharmacokinetic properties of the conjugated molecule in circulation, while also enabling controlled release of the photodynamic agent inside the target cell. The linker acts as a protective intermediary that preserves solubility during transport but allows activation at the target site.
Solution Approach 2:
The patent applies composite material principles by creating a conjugated molecule that combines different functional components: the hydrophilic folate ligand for targeting and solubility, the releasable linker for controlled delivery, and the photodynamic agent for therapeutic activity. This composite structure integrates the advantages of each component while mitigating their individual limitations, achieving both high specificity and optimized pharmacokinetic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agents demonstrate high specificity and efficacy in targeting and destroying cancer cells with minimal toxicity to healthy tissues, achieving complete tumor cure with no recurrence in animal models.
Implementation Method 1
The agents demonstrate high specificity and efficacy in targeting and destroying cancer cells with minimal toxicity to healthy tissues
Implementation Method 2
using a releasable linker to enhance water solubility and specificity, thereby overcoming the limitations of conventional therapies
Implementation Method 3
conjugated to ligand, such as folic acid or folate, that targets a receptor overexpress in a pathogenic/diseased cell
Data Source
AI summary
The present invention describes new compounds that are useful for image-guided surgery and photodynamic therapy. In particular the compounds may be targeted to the nucleus or the mitochondria after compounds were delivered to diseased tissues such as cancer using a ligand that target receptor that express on the diseased tissue and followed by receptor mediated endocytosis and provide effective activity against cancer cells as well as other disorders. Methods and compositions for use of the same are described.